What menopausal hormone therapy can do, how the components differ, and why route and timing change the conversation.
Sep 2026 · Five minutes.
Menopausal hormone therapy — MHT, also called HRT — is the most effective treatment for hot flashes and night sweats, and an evidence-based option for preventing bone loss in appropriate candidates.
It is not a longevity prescription and not a one-size-fits-all protocol. The decision depends on symptoms, age, time since menopause, uterus status, medical history, personal priorities, and the specific hormone, dose, route, and duration used.
I do not prescribe. What I can do is help you walk into that appointment understanding the shape of the conversation.
Systemic estrogen reaches tissues throughout the body and is the primary component for vasomotor symptoms. It can also improve sleep when the disruption is driven by night sweats, and it helps prevent the accelerated bone loss associated with menopause.
It comes as transdermal patches, gels or sprays, and oral tablets. Treatment usually aims for the lowest effective dose that meets your goals, rather than a predetermined "optimal" blood level.
Oral estrogen passes through the liver first, with greater effects on hepatic proteins, triglycerides, clotting factors, and sex-hormone-binding globulin. Transdermal estradiol enters circulation through the skin and largely avoids that first pass.
Observational evidence suggests transdermal estrogen may carry a lower venous-thromboembolism risk than oral, which matters when clotting or metabolic risk is part of the picture.
Systemic estrogen stimulates the endometrium. In a woman with an intact uterus, adequate progesterone or another progestogen is generally required to reduce the risk of endometrial hyperplasia and cancer. The dose and schedule have to provide sufficient protection for the estrogen regimen being used.
Micronized progesterone is chemically identical to the progesterone your body makes. Synthetic progestogens have different molecular and metabolic profiles.
A formulation note worth raising with your pharmacist: many US oral micronized progesterone capsules contain peanut oil and are contraindicated with peanut allergy. Formulations differ by manufacturer.
Oral micronized progesterone is metabolized into neuroactive compounds, including allopregnanolone, that interact with GABA-A receptors. That helps explain why some women feel sleepy, or sleep better, when it is taken at night.
Responses vary, and sedation, dizziness, or mood effects can occur. Progesterone should not be added or adjusted for sleep alone without considering the whole regimen.
For many healthy symptomatic women younger than sixty, or within about ten years of menopause onset, without contraindications, the major menopause societies describe the benefit-risk balance as generally favorable.
Starting much later needs a different assessment, because absolute cardiovascular, stroke, and thrombotic risks rise with age and time since menopause. This is a framework for shared decision-making, not an expiration date.
MHT may be chosen to treat symptoms, with bone protection as an additional benefit. It should not be started solely to prevent cardiovascular disease or dementia.
The reason for treatment matters, because it shapes how benefits, risks, dose, route, and duration are weighed.